#ESC22: 89bio heads toward PhIII in severe hypertriglyceridemia, a field left behind by Pfizer earlier this year 

BARCELONA — Two months after revealing the topline data — and quickly going to the market for a capital infusion of $95 million — 89bio is now presenting the mid-stage results of its high-triglyceride drug at the European Society of Cardiology Congress.

In patients with severe hypertriglyceridemia (SHTG) — in…